Study of effects of ifenprodil in patients with methamphetamine dependence: Protocol for an exploratory, randomized, double-blind, placebo-controlled trial.
G protein-activated inwardly rectifying potassium channel
ifenprodil
methamphetamine dependence
randomized, double-blind, placebo-controlled trial
Journal
Neuropsychopharmacology reports
ISSN: 2574-173X
Titre abrégé: Neuropsychopharmacol Rep
Pays: United States
ID NLM: 101719700
Informations de publication
Date de publication:
06 2019
06 2019
Historique:
received:
09
11
2018
revised:
17
01
2019
accepted:
20
01
2019
pubmed:
14
2
2019
medline:
13
8
2020
entrez:
14
2
2019
Statut:
ppublish
Résumé
Pharmacotherapy for methamphetamine dependence has not yet been developed in Japan or elsewhere in the world. Ifenprodil is a blocker of G protein-activated inwardly rectifying potassium channels that play a key role in the mechanism of action of addictive substances. Our aim is to examine the safety, efficacy, and outcomes of ifenprodil for the treatment of methamphetamine dependence in a randomized, double-blind, placebo-controlled trial. The recruitment of outpatients with methamphetamine dependence began in January 2018. The patients will be randomized into three arms: placebo, 60 mg/d ifenprodil, or 120 mg/d ifenprodil. Placebo or ifenprodil will be taken for 84 days. We will use Cerocral fine granule 4% This study is the first clinical trial of ifenprodil treatment for methamphetamine dependence and is designed as an intervention test with off-label drug use. The present study is expected to provide evidence of the effects of ifenprodil treatment on methamphetamine dependence. This trial was registered in the UMIN clinical trial registry (UMIN000030849; date of registration: January 17, 2018).
Identifiants
pubmed: 30756527
doi: 10.1002/npr2.12050
pmc: PMC7292268
doi:
Substances chimiques
Piperidines
0
Potassium Channel Blockers
0
Methamphetamine
44RAL3456C
ifenprodil
R8OE3P6O5S
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
90-99Informations de copyright
© 2019 The Authors. Neuropsychopharmacology Reports published by John Wiley & Sons Australia, Ltd on behalf of The Japanese Society of Neuropsychopharmacology.
Références
Fundam Clin Pharmacol. 2016 Jun;30(3):282-9
pubmed: 26751259
Neuropsychopharmacol Rep. 2018 Mar;38(1):9-17
pubmed: 30106266
Science. 1986 Dec 5;234(4781):1261-5
pubmed: 2430334
J Forensic Leg Med. 2017 Jan;45:36-40
pubmed: 27987415
Neuropsychopharmacol Rep. 2019 Jun;39(2):90-99
pubmed: 30756527
Neuropsychopharmacology. 2003 May;28(5):932-8
pubmed: 12637950
J Pharmacol Sci. 2008 Jan;106(1):2-8
pubmed: 18198474
J Med Chem. 1991 Oct;34(10):3085-90
pubmed: 1681106
Neurosci Res. 2000 Sep;38(1):113-6
pubmed: 10997585
Seishin Shinkeigaku Zasshi. 2010;112(9):877-84
pubmed: 21077296
PLoS One. 2016 Mar 11;11(3):e0151242
pubmed: 26968030
J Neurosci. 1996 Jun 1;16(11):3559-70
pubmed: 8642402
Curr Neuropharmacol. 2011 Mar;9(1):68-72
pubmed: 21886565
J Biol Chem. 1995 Dec 1;270(48):28660-7
pubmed: 7499385
GeoJournal. 2013 Jun 1;78(3):451-462
pubmed: 23750069
Pain. 2005 Jan;113(1-2):9-19
pubmed: 15621359
Biochem Biophys Res Commun. 1995 Mar 28;208(3):1166-73
pubmed: 7702616
Arch Iran Med. 2015 Jan;18(1):28-33
pubmed: 25556383
J Food Drug Anal. 2013 Dec;21(4):S33-S36
pubmed: 25278734
Nature. 1986 Jan 30-Feb 5;319(6052):405-7
pubmed: 2418362
J Neurosci. 1999 Feb 1;19(3):1006-17
pubmed: 9920664
Curr Drug Targets. 2001 Sep;2(3):285-98
pubmed: 11554553
Int J Neuropsychopharmacol. 2016 Jul 05;19(7):
pubmed: 27207905
Behav Res Ther. 1979;17(2):157-60
pubmed: 426744
Addiction. 2014 Sep;109(9):1489-500
pubmed: 24825486
Drug Alcohol Depend. 2007 May 11;88(2-3):174-81
pubmed: 17118576
Nat Neurosci. 2004 Feb;7(2):153-9
pubmed: 14745451
Nat Neurosci. 1999 Dec;2(12):1091-7
pubmed: 10570486
Proc Natl Acad Sci U S A. 1993 Nov 1;90(21):10235-9
pubmed: 8234283
Neuroscience. 1985 Jan;14(1):95-101
pubmed: 2579354
Nihon Shinkei Seishin Yakurigaku Zasshi. 2011 Apr;31(2):95-6
pubmed: 21618903
Addiction. 2013 Apr;108(4):751-61
pubmed: 23186131
Daru. 2015 Jan 15;23:2
pubmed: 25588930
FEBS Lett. 1996 Jan 22;379(1):31-7
pubmed: 8566224
Proc Natl Acad Sci U S A. 1989 May;86(9):3419-22
pubmed: 2566172
J Consult Clin Psychol. 1979 Feb;47(1):204-6
pubmed: 429662
Nature. 1995 Mar 9;374(6518):135-41
pubmed: 7877685
Mol Endocrinol. 1997 May;11(5):527-37
pubmed: 9139797
Ann N Y Acad Sci. 2006 Aug;1074:295-302
pubmed: 17105925
Neuropsychopharmacology. 2006 Mar;31(3):516-24
pubmed: 16123769
Addiction. 2010 Jan;105(1):146-54
pubmed: 19839966
Life Sci. 1999;64(12):PL151-6
pubmed: 10210291